Drug intelligence / Profile preview

ieramilimab + spartalizumab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ieramilimab + spartalizumab is a combination immunotherapy approach that pairs two monoclonal antibodies targeting different immune checkpoint proteins. Ieramilimab is a humanized IgG4 monoclonal antibody that targets LAG-3 (Lymphocyte Activating 3), while spartalizumab is a humanized IgG4 monoclonal antibody that targets PD-1 (programmed death-1). The combination aims to enhance anti-tumor immune responses by simultaneously blocking two inhibitory pathways that suppress T cell function.

Brand names: spartalizumabieramilimab
Other names: ieramilimab + spartalizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ieramilimab + spartalizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ieramilimab + spartalizumab.

Explore the full profile